Cranbury, United States
Founded in 2001 and headquartered in the United States, Cornerstone Pharmaceuticals aims to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues. The company's lead drug, CPI-613, targets enzymes involved in cancer cell energy metabolism and is being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent and in combination with standard drug therapy.
With a focus on attacking regulatory processes exclusive to cancer cells, Cornerstone Pharmaceuticals aims to improve the safety profile and efficacy of cancer treatment. As the company continues to advance its groundbreaking research in altered cancer metabolism directed therapies, it presents an opportunity for venture capitalists to support innovative approaches to tackling challenging aspects of cancer treatment. While the specific details of the last investment and investors are not available, the potential for investing in Cornerstone Pharmaceuticals aligns with the growing interest in biotechnology and pharmaceutical companies at the forefront of developing targeted therapies for cancer.
